OvaScience, a Cambridge company specializing in fertility treatments, announced Wednesday that it has completed a $37 million Series B financing.
The financing was led by General Catalyst. Existing investors, Bessemer Venture Partners and Longwood Fund, were joined by new investors BBT Capital Management Advisors, LLC, Cycad Group, Hunt BioVentures, and RA Capital, among others. Leerink Swann LLC acted as lead placement agent for the offering.
In a press release, OvaScience said it plans to use the proceeds from the financing to support the development and commercialization of its fertility treatment approaches based on the egg precursor cell discoveries of OvaScience cofounder Jonathan Tilly.
Tilly is director of the Vincent Center for Reproductive Biology and chief of research for Massachusetts General Hospital’s Vincent Department of Obstetrics and Gynecology. He is also a professor at the Harvard Medical School.